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peak	 velocity	 versional	 dysconjugacy	 index	 (PV‐VDI)	 and	 first‐pass	 amplitude	VDI	
(FPA‐VDI).	Both	parameters	were	compared	between	fampridine	and	placebo	using	a	








Conclusion: Fampridine	 improves	 saccadic	 eye	 movements	 due	 to	 INO	 in	 MS.	
Treatment	response	to	fampridine	may	gauge	patient	selection	for	inclusion	to	remy‐
elination	 strategies	 in	 MS	 using	 saccadic	 eye	 movements	 as	 primary	 outcome	
measure.
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1  | INTRODUC TION
Successful	 remyelination	 remains	 the	Holy	Grail	 for	 the	 treatment	
of	multiple	 sclerosis	 (MS),	 a	 predominantly	 demyelinating	 disease.	
In	 a	 proof‐of‐principle	 study,	 it	 has	 been	 shown	 that	 Clemastine	




myelination	strategies	 in	MS.2	 In	optic	neuritis,	 there	 is	consistent	











Demyelination	 in	MS	does	affect	a	 functionally	 relevant	 single	
axon	pathway,	 the	medial	 longitudinal	 fasciculus	 (MLF).5	A	MS	 le‐
sion	in	the	MLF	causes	an	internuclear	ophthalmoparesis	which	can	
be	 aggravated	 though	Uhthoff's	 phenomenon	 indicating	 function‐
ing	 axons	 with	 alterable	 conduction	 velocities.6,7	 Rapid	 (saccadic)	
horizontal	 adducting	 eye	movements	 are	 impaired	 in	 an	 INO,	 and	














velocity	 versional	 dysconjugacy	 index	 (PV‐VDI)	 and	 the	 first‐pass	
amplitude	VDI	(FPA‐VDI).14
In	 this	 study,	 we	 tested	 whether	 a	 drug	 known	 to	 accelerate	
nerve	conduction,	fampridine	(dalfampridine),	has	an	effect	on	sac‐
cadic	eye	movements	in	patients	with	MS	who	suffer	from	an	INO.	
Previously	 fampridine,	 a	 voltage‐gated	 potassium	 channel	 blocker	
was	shown	to	improve	walking	speed	in	patients	with	MS.15	A	year	
later,	 fampridine	 was	 approved	 by	 the	 FDA	 for	 treating	 impaired	
walking	 in	 MS	 patients.	 Since,	 the	 anecdotal	 evidence	 has	 been	
published	showing	three	cases	of	oral	Fampridine	 (10	mg)	 improv‐




2  | MATERIAL S AND METHODS
This	 single‐center,	 double‐blind,	 randomized	 placebo‐controlled	
cross‐over	 study	 was	 conducted	 by	 the	 Centre	 for	 Human	 Drug	
Research	(Leiden,	the	Netherlands)	between	April	2015	and	August	
2016.	 This	 study	was	 approved	 by	 the	Medical	 Ethics	Committee	
of	 the	 BEBO	 Foundation	 (Assen,	 the	 Netherlands)	 and	 was	 con‐
ducted	 in	 accordance	 with	 the	 Dutch	 Act	 on	 Medical	 Research	
Involving	 Human	 Subjects	 (WMO)	 and	 in	 compliance	 with	 Good	















between	 the	occasions	was	at	 least	1	week,	which	 is	more	 than	5	
half‐lives	of	fampridine,	thereby	guaranteeing	an	adequate	washout.
All	 patients	 had	 a	 diagnosis	 of	 clinically	 definite	MS	 based	 on	
the	2010	revision	of	the	McDonald	criteria.17 The disease duration 
had	to	be	longer	than	1	year	and	the	time	from	last	relapse	at	least	
30	days.	All	 patients	were	 screened	using	 a	prosaccadic	 task.	The	
presence	 of	 INO	 (unilateral	 or	 bilateral)	was	 determined	 by	 visual	
examination	of	the	graphs	depicting	horizontal	gaze	position	by	two	









The	 randomization	was	 created	by	 an	 independent	 statistician	
at	the	Centre	for	Human	Drug	Research	using	SAS	version	9.4.	Only	
independent	staff	members	at	the	trial	pharmacy	of	the	Amsterdam	




monly	 prescribed	 daily	 dose	 of	 fampridine	 is	 20	mg.	 To	 ensure	




dose	 of	 fampridine	 on	 INO,	we	 administered	 a	 single	 20	mg	 dose	
of	 fampridine	 in	order	 to	 increase	 the	 likelihood	of	demonstrating	












2‐8°C;	 the	 plasma	 fractions	were	 then	 transferred	 to	 2‐mL	 tubes	
and	were	 stored	 at	 −20°C	within	 30	minutes	 of	 sampling.	 Plasma	
fampridine	 concentration	 was	 measured	 using	 ultra‐performance	
liquid	chromatography‐tandem	mass	spectrometry	(UPLC‐MS/MS).	




















The	 data	 were	 analyzed	 off‐line	 using	 custom‐made	 software	








Brain	 imaging	 was	 performed	 by	 magnetic	 resonance	 imaging	
(MRI).	We	used	a	3	Tesla	machine	 (Discovery	MR750	3.0T	whole‐
body	MR	 system,	 GE	 Healthcare).	 A	 multisequence	MRI	 protocol	
was	performed,	including	axial	T1‐weighted	spin	echo,	axial	proton	
density	 (PD),	 T2‐weighted	 fast	 spin	 echo,	 3D	 fluid‐attenuated	 in‐
version	 recovery	 (FLAIR),	 coronal	 T2	 short	 tau	 inversion	 recovery	
(STIR),	3D	T1‐weighted	fast‐spoiled	gradient	echo	(FSPGR),	and	axial	










Institute	 Inc.,	 Cary,	 NC,	 USA).	 To	 determine	 whether	 significant	
treatment	effects	could	be	detected	using	the	saccadic	protocol,	the	
PV‐VDI	 and	FPA‐VDI	were	analyzed	using	a	mixed	model	 analysis	
of	 covariance	 (ANCOVA).	 Treatment,	 time,	 period,	 and	 treatment	





relative	 to	 baseline	 value	was	 analyzed	 using	 the	 same	model	 for	
graphical	purposes.	We	used	the	Spearman	rank	correlation	test	to	
measure the correlation between baseline characteristics and treat‐
ment	 conditions.	 For	 the	 eye‐tracking	 tests,	 individual	 INOs	were	
treated	as	 individual	 subjects	 in	both	 the	ANCOVA	and	Spearman	
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baseline	calculated	to	−17.4%	(95%	CI:	−22.4%,	−12.1%;	P	<	0.0001,	
Table	2).	 Similar	 results	 were	 obtained	 for	 FPA‐VDI	 (Figure	3B),	





The	magnitude	of	 improvement	of	 saccadic	eye	movements	 in	
INO	was	directly	correlated	to	the	PV‐VDI	and	FPA‐VDI	at	baseline	








for	 at	 least	 5	hours	 which	 parallels	 the	 robust	 pharmacodynamic	
F I G U R E  1  CONSORT	flow	diagram	for	
the	randomized	controlled	trial
Contacted and screened 
by phone (n = 132)
INO screening (n = 66)
Medical screening (26)
Trial parcipaon and 
compleon (n = 24)




No INO (n = 1)
Excluded:
Did not meet inclusion 
criteria (n = 2)
Excluded:
- No INO (n = 42)
- Eligible but not interested (n = 2)
Excluded: 
- Did not meet inclusion criteria 
(n = 32)
- Unable to contact (n = 18)
- Eligible but not interested (n = 16)
TA B L E  1  Subject	characteristics








F I G U R E  2  Mean	fampridine	serum	concentrations	with	SD,	
measured	in	the	subjects	during	the	occasion

















































cadic	 abduction/adducting	eye	peak	velocities	 for	 the	worst	 INO”	
after	 treatment	with	 fampridine.16	 In	 other	 words,	 fampridine	 re‐
duces	on	a	patient	 level	 the	pathological	slowing	of	 the	adducting	
eye	in	an	INO.	Furthermore,	the	pharmacodynamic	data	exclude	the	







































































Estimate of the 
difference (%)
95% CI
P‐valueLower (%) Upper (%)
VDI	peak	velocity	(%),	
eyes	with	INO
−17.4 −22.4 −12.1 <0.0001
VDI	peak	velocity	(%),	
eyes	without	INO
−4.6 −10.3 1.5 0.105
VDI	first‐pass	amplitude	
(%),	eyes	with	INO
−12.1 −17.6 −6.2 0.0003
TA B L E  2  Analysis	results	table	
video‐oculography
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